Cameron Inquiry

Last updated

The Cameron Inquiry, formerly the Commission of Inquiry on Hormone Receptor Testing, is a Canadian public judicial inquiry into the conduct of the Newfoundland and Labrador Eastern Health authority. The inquiry is investigating whether Eastern Health was at fault in the reporting of erroneous and delayed test results to breast cancer patients between 1997 and 2005, and in then failing to report the full scope of these errors. The inquiry developed ramifications for regional and national politics as the opposition Liberal Party questioned why the regional Progressive Conservative Party government had not intervened sooner in the crisis, and said that former deputy health minister Robert Thompson, who had been appointed to chair the inquiry, should stand down, prompting Newfoundland and Labrador premier Danny Williams to accuse the Liberals of a smear campaign. [1] The inquiry, chaired by Justice Margaret Cameron, was called in May 2007 [2] and released a report in March 2009. [3]

Contents

Background

In May 2005 Eastern Health discovered errors in hormone receptor breast cancer test results from a histology lab in St. John's, Newfoundland. The tests were designed to register patients' hormone levels, and determine whether they could benefit from potentially life-saving hormone oncology treatments. [4] The board commissioned the re-testing of results from up to 1,500 patients and alerted the office of premier Danny Williams of this development and of potential ensuing media interest. [5] An hour after first contacting Williams's office, the board sent a second message with what communications director Karen Matthews described to the inquiry as a "stand-down" notice, saying the issue had been minimized; Matthews responded by withdrawing the office from high alert over the case. [5] Former health minister John Ottenheimer told the inquiry that he wished to publicize the testing failures when they emerged in May 2005, but deferred to Eastern Health's request that he leave them to handle the affair internally. [6]

After retesting, Eastern Health concluded that 386 patients had received erroneous results, [2] of whom 117 required a change to their treatment programs [7] In December 2006 the board held a series of media briefings on the hormone receptor test errors, downplaying the seriousness and extent of the problems. [8]

Despite the apparent conclusiveness of the inquiry report, epidemiological evidence to support such conclusions is lacking. The testing errors are expected in medical practice, and retesting of tissues over long period of time remains a controversial exercise due to the following factors leading to bias: 1. fluid state of medical technology 2. change in medical practice patterns and criteria for test interpretation 3. effects of prevalence in diagnostic testing. If one examines the test performed in 1998 using the technology of 2008, the inherited time bias is unavoidable. Nevertheless, even despite these biases, the clinical epidemiology of medical testing robustly predicts the expected test errors (due to test characteristics rather than due to problems with test performance) and these are closely matching the observed errors uncovered by Cameron Inquiry.

Any medical test with 90% sensitivity and 90% specificity (and this was declared as a standard performance of ER and PR test in breast cancer in 2010 by ASCO) will not be expected to result in only 10% of false negative and 10% of false positive results. The expected test errors are subject to effect of prevalence in medical testing. Actual prevalence of ER positive breast cancer is in a range of 80%. By re-testing negative results the pathologists, in fact, tried to determine negative predictive value (NPV) of the test (i.e. derive how many negative test results were true negative against reference laboratory). NPV is not a fixed or stable parameter of the test, as it will change with prevalence (interested readers can be referred to Bayesian methods in diagnostic testing). By making simple NPV formula calculations using the above listed test parameters one can derive negative predictive value of only about 60 - 65% (for a 90% sensitive and 90% specific test under condition of 80% prevalence of ER positive breast cancers in North American population). The expected error (false negative results) under such condition of prevalence will be close to 35-40% (1- negative predictive value).

Formula

Negative predictive value =  True negative/ (Total tested negative)   x 100, %

This should not be confused with the fixed parameters of test performance - sensitivity and specificity.

Reference : Hunink M. et al Decision Analysis in Health and Medicine, 2012.

Press reports

In May 2007 the Canadian Broadcasting Company (CBC) published reports showing that Eastern Health knew the error rate for the screening tests to have been around 42%, considerably higher than the figure they disclosed in the December 2006 media briefings. [5]

The provincial government then called a judicial inquiry, commencing November 2007, into Eastern Health's actions.

Conduct of the inquiry

The inquiry saw dozens of witnesses between November 2007 and October 2008. In May 2008 the provincial government questioned the length of time the inquiry was taking, with justice minister Jerome Kennedy suggesting that continuing with the tone, style, and procedure of the inquiry could cause the health system to collapse. [9] Chair Margaret Cameron declined the government's application to prevent inquiry lawyers from cross-examining witnesses, which had been presented as an attempt to expedite the inquiry.

Opposition leader Yvonne Jones accused premier Williams of trying to "undermine" the inquiry by questioning testimony and witness examination procedures, including one occasion on which Williams described the inquiry in May 2008 as a "witch hunt." [10] Jones also said that former deputy health minister Robert Thompson, a Progressive Conservative who had been commissioned to oversee the inquiry, had a conflict of interest and should stand down. Williams responded critically to what he called an attempt by Jones to smear senior public health officials. [1]

Peter Dawe of the Canadian Cancer Society objected to Williams's perceived attempts to speed up the inquiry, saying that patients deserved a full investigation however long it took. [10]

Inquiry report

The inquiry finished hearing testimony in October 2008 and was due to report by March 1, 2009. [11]

Lawsuit

In 2007, after the revelation that Eastern Health had deliberately concealed the scope of the testing errors, hundreds of patients filed a class action lawsuit against Eastern Health over the affair. [12] A $17.5 million settlement was reached in 2009. [13]

See also

Related Research Articles

<span class="mw-page-title-main">Breast cancer</span> Cancer that originates in mammary glands

Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin.

In evidence-based medicine, likelihood ratios are used for assessing the value of performing a diagnostic test. They use the sensitivity and specificity of the test to determine whether a test result usefully changes the probability that a condition exists. The first description of the use of likelihood ratios for decision rules was made at a symposium on information theory in 1954. In medicine, likelihood ratios were introduced between 1975 and 1980.

<span class="mw-page-title-main">Positive and negative predictive values</span> In biostatistics, proportion of true positive and true negative results

The positive and negative predictive values are the proportions of positive and negative results in statistics and diagnostic tests that are true positive and true negative results, respectively. The PPV and NPV describe the performance of a diagnostic test or other statistical measure. A high result can be interpreted as indicating the accuracy of such a statistic. The PPV and NPV are not intrinsic to the test ; they depend also on the prevalence. Both PPV and NPV can be derived using Bayes' theorem.

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type (NST) is also referred to as invasive ductal carcinoma or infiltrating ductal carcinoma(IDC) and invasive ductal carcinoma, not otherwise specified (NOS). Each of these terms represents to the same disease entity, but for international audiences this article will use invasive carcinoma NST because it is the preferred term of the World Health Organization (WHO).

MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. It gives a binary result, high-risk or low-risk classification, and helps physicians determine whether or not a patient will benefit from chemotherapy. Women with a low risk result can safely forego chemotherapy without decreasing likelihood of disease free survival. MammaPrint is part of the personalized medicine portfolio marketed by Agendia.

<span class="mw-page-title-main">Sensitivity and specificity</span> Statistical measures of the performance of a binary classification test

Sensitivity and specificity mathematically describe the accuracy of a test that reports the presence or absence of a condition. If individuals who have the condition are considered "positive" and those who do not are considered "negative", then sensitivity is a measure of how well a test can identify true positives and specificity is a measure of how well a test can identify true negatives:

Medical statistics deals with applications of statistics to medicine and the health sciences, including epidemiology, public health, forensic medicine, and clinical research. Medical statistics has been a recognized branch of statistics in the United Kingdom for more than 40 years but the term has not come into general use in North America, where the wider term 'biostatistics' is more commonly used. However, "biostatistics" more commonly connotes all applications of statistics to biology. Medical statistics is a subdiscipline of statistics. "It is the science of summarizing, collecting, presenting and interpreting data in medical practice, and using them to estimate the magnitude of associations and test hypotheses. It has a central role in medical investigations. It not only provides a way of organizing information on a wider and more formal basis than relying on the exchange of anecdotes and personal experience, but also takes into account the intrinsic variation inherent in most biological processes."

<span class="mw-page-title-main">Medical test</span> Medical procedure

A medical test is a medical procedure performed to detect, diagnose, or monitor diseases, disease processes, susceptibility, or to determine a course of treatment. Medical tests such as, physical and visual exams, diagnostic imaging, genetic testing, chemical and cellular analysis, relating to clinical chemistry and molecular diagnostics, are typically performed in a medical setting.

Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification. Triple-negative is sometimes used as a surrogate term for basal-like.

<span class="mw-page-title-main">Tom Osborne (Canadian politician)</span> Canadian politician

Tom Osborne is a politician in Newfoundland and Labrador, Canada. He represents the district of Waterford Valley in the Newfoundland and Labrador House of Assembly. He is a member of the Liberal Party, a former member of the Progressive Conservative Party, and a former Minister in Danny Williams' first cabinet. He is currently Minister of Health and Community Services in the Furey government.

John Ottenheimer is a Canadian lawyer and politician in Newfoundland and Labrador, Canada. Ottenheimer is a former Cabinet minister in the government of Danny Williams and represented the district of St. John's East for the Progressive Conservative Party from 1996 to 2007. He unsuccessfully ran for the leadership of the Progressive Conservatives in 2014 losing to Paul Davis.

Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy and systemic treatment. Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes.

The estrogen receptor test (ERT) is a laboratory test to determine whether cancer cells have estrogen receptors. This information can help establish how the cancer should be treated.

Margaret A. Cameron is a Canadian jurist and current Justice of the Supreme Court of Newfoundland and Labrador.

Breast cancer classification divides breast cancer into categories according to different schemes criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes. As knowledge of cancer cell biology develops these classifications are updated.

A CDK inhibitor is any chemical that inhibits the function of CDKs. They are used to treat cancers by preventing overproliferation of cancer cells. The US FDA approved the first drug of this type, palbociclib (Ibrance), a CDK4/6 inhibitor, in February 2015, for use in postmenopausal women with breast cancer that is estrogen receptor positive and HER2 negative. Several compounds are in clinical trials.

Pre-test probability and post-test probability are the probabilities of the presence of a condition before and after a diagnostic test, respectively. Post-test probability, in turn, can be positive or negative, depending on whether the test falls out as a positive test or a negative test, respectively. In some cases, it is used for the probability of developing the condition of interest in the future.

<span class="mw-page-title-main">Gynecomastia</span> Endocrine system disorder of human male breast

Gynecomastia is the abnormal non-cancerous enlargement of one or both breasts in males due to the growth of breast tissue as a result of a hormone imbalance between estrogens and androgens. Gynecomastia can cause significant psychological distress or unease.

<span class="mw-page-title-main">Ches Crosbie</span> Canadian politician

Chesley Furneaux "Ches" Crosbie, is a Canadian lawyer and former politician. Crosbie was elected leader of the Progressive Conservative Party of Newfoundland and Labrador on April 28, 2018 serving until March 31, 2021. He served as the Leader of the Opposition in the Newfoundland and Labrador House of Assembly from 2018 until 2021.

References

  1. 1 2 "Liberals cite cancer inquiry conflict". CBC News . 9 April 2008. Archived from the original on 13 November 2012.
  2. 1 2 Sweet, Barb (September 11, 2008). "Doctor regrets her part in decision not to disclose test results". The Telegram. St. John's. Archived from the original on 10 August 2011.
  3. ↑ "Government Releases Cameron Inquiry Report". Government of Newfoundland and Labrador. March 3, 2009.
  4. ↑ "Never wanted test result problems disclosed, manager tells cancer probe". CBC News. 23 October 2008. Archived from the original on 13 November 2012. Retrieved 6 February 2009.
  5. 1 2 3 "Premier's office did not see alarm of cancer tests, inquiry told". CBC News. June 10, 2008. Archived from the original on 11 June 2008.
  6. ↑ "Premier's office felt Eastern Health handling crisis, Cameron Inquiry told". The Telegram. Archived from the original on 9 September 2018. Retrieved 6 February 2009.
  7. ↑ "Oncologist apologizes to patients at breast cancer inquiry". CBC News. 19 September 2008. Archived from the original on 4 November 2012. Retrieved 6 February 2009.
  8. ↑ "Little comfort level with cancer numbers, MD tells inquiry". CBC News. 26 May 2008. Archived from the original on 4 November 2012. Retrieved 6 February 2009.
  9. ↑ "No curbs on lawyers, Cameron inquiry tells N.L." CBC News. May 24, 2008. Archived from the original on 26 May 2008. Retrieved 6 February 2009.
  10. 1 2 "Williams rejects bullying accusations over cancer inquiry". CBC News. 13 May 2008. Archived from the original on 13 May 2008. Retrieved 6 February 2009.
  11. ↑ "Not given lab results until this year, final witness tells cancer probe". CBC News. 31 October 2008. Retrieved 6 February 2009.
  12. ↑ "Judge needed for clarity in breast cancer negotiations: lawyer". CBC News. 8 October 2008. Archived from the original on 4 November 2012. Retrieved 6 February 2009.
  13. ↑ "N.L.'s Eastern Health Authority settles $17M lawsuit". CBC News. 31 October 2009. Retrieved 5 September 2012.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.